Relugolix - Takeda

Drug Profile

Relugolix - Takeda

Alternative Names: TAK-385

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Myovant Sciences; Takeda; Takeda Oncology
  • Class Analgesics; Antineoplastics; Ketones; Pyrimidines; Small molecules
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pain; Prostate cancer; Uterine leiomyoma
  • Phase I Solid tumours

Most Recent Events

  • 03 Oct 2017 Safety and efficacy data from a phase III trial in Uterine leiomyoma released by Takeda Pharmaceutical
  • 30 Aug 2017 Myovant Sciences initiates enrolment in the SPIRIT 2 trial for Pain (Monotherapy and Combination Therapy) in USA (NCT03204331)
  • 04 Jul 2017 Myovant Sciences plans the SPIRIT 2 phase III trial for Endometriosis-associated pain (NCT03204331)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top